Stomach cancer (credit: canva)
Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).
A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:
1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.
2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.
3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.
4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.
5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding
There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.
Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.
1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.
2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.
3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.
He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.
Credit: AI
The boom in GLP-1 drugs for diabetes and obesity management is not without its drawbacks. From vision loss to hair fall, researchers are increasingly assessing the side effects of popular weight loss medicines, which include semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound).
Recently, a new side effect among GLP-1 users was reported which entails detachment of the nails. Experts believe that using weight loss injections may cause the patient’s fingernails to fall off, raising fresh concerns about the short as well as long-term side effects of these medicines.
Nail detachment, clinically known as onycholysis, is a condition in which nails separate from the skin underneath it.
A new study has found that the risk of fingernails falling off in people taking GLP-1 receptor agonists was almost four times more common than non-users. The findings were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026.
Researchers, led by Dr. Charles Taïeb, found that 39% of GLP-1 users reported nail detachment, compared to 9% of people in the comparison group. Overall, 66% of people taking GLP-1 drugs experienced at least one nail disorder.
Apart from nail falling off, nail discolouration was also seen frequently among users, affecting 46% compared to 17% of non-users.
Researchers described this as the first controlled study specifically examining the possible effects of GLP-1 receptor agonists on nail health.
Also read: New Experimental Drug May Preserve Muscle Mass During Weight Loss From Ozempic
GLP-1 medicines like semaglutide and tirzepatide reduce appetite, which can lead people to eat way less than they normally do. Rapid or significant weight loss can sometimes affect the body's supply of protein and other nutrients needed for healthy hair and nail growth.
But the increased number of nail detachment cases seen among GLP-1 drug users could not be solely attributed to weight loss.
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” said study author Dr Charles Taïeb. “Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
The researchers stress that the study cannot establish that GLP-1 receptor agonists caused changes to the nails. Around half of users already had nail problems before the treatment began.
After adjusting dermatological conditions and nutritional deficiencies, the strength of some associations reduced. However, nail detachment and nail discolouration remained around two to three times more frequent among users after adjustment.
Dermatologists already recognise that GLP-1 treatment can cayuse brittle nails and slower nail growth, especially in people who lose substantial weight loss. The American Academy of Dermatology notes that these effects may occur alongside other changes to the skin and hair.
Also read: 2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 Drugs
A companion study also identified unusual changes on the hair and scalp among GLP-1 users. Unusual hair loss was reported by 50% of GLP-1 users compared to 34% of controls.
The study also reported loss of hair volume or density affected 42% versus 19% among controls. Hair loss after the treatment was also more than twice as common among users, i.e. 26% among users compared to 12% in non-users. Redness of the scalp was also around three times more frequent.
Study author Dr Bruno Halioua explained, “This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component.”
The author added, “Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable. Taken together, our findings suggest that factors beyond weight loss alone may contribute to the hair, scalp and nail changes observed among GLP-1 users.”
He also said that these changes could be temporary and that one should not stop the treatment without discussing it with their doctor.
“These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative,” he said. “Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy.”
Credit: iStock
Chewing tobacco contributed to an estimated 251,000 deaths globally in 2023, according to a new study from the Institute for Health Metrics and Evaluation (IHME).
The analysis, part of the Global Burden of Disease Study 2023 (GBD 2023) and published in The Lancet Global Health, found that more than 90% of the health burden was concentrated in 10 countries, with India accounting for the largest share.
"Chewing tobacco is not a uniform public health problem, and our findings show that a relatively small number of countries bear an overwhelming share of its health burden," said Gabriela Gil, lead author and research scientist at IHME.
Also read: Trying For A Baby? Tobacco Smoking Hurting Male And Female Fertility, Warns WHO
South Asia accounted for an estimated 210,000 chewing tobacco-related deaths, or about 84% of the global total.
Nearly 15% of people aged 15 and older in the region used chewing tobacco in 2023.
The highest age-standardized prevalence was reported in:
India recorded the highest number of chewing tobacco-related deaths among both males and females.
More than 90% of the male death and disability burden was concentrated in:
Among females, the countries were:
Read More: Trying to Quit Tobacco? Yoga Could Improve Your Chances, Suggests Study
Globally, use was higher among males than females and increased with age before peaking at 60–64 years.
In South Asia:
Bangladesh showed a different pattern, with female use higher than male use across age groups older than 30.
"These findings show why chewing tobacco control cannot take a one-size-fits-all approach," said Dr. Emmanuela Gakidou, senior author and professor in the Department of Health Metrics Sciences at IHME.
"Prevention and cessation strategies need to reflect how patterns of use differ by country, age and sex, as well as the cultural and social factors that shape tobacco use in each setting," Dr Gakidou added.
Researchers assessed chewing tobacco-related burden across six outcomes:
Stroke accounted for the largest share of health loss, at 55.9 disability-adjusted life-years (DALYs) per 100,000 people, followed by lip and oral cavity cancer at 17.4 DALYs per 100,000.
Chewing tobacco accounted for 17.3% of lip and oral cavity cancer DALYs globally, rising to 30.5% in South Asia.
Chewing tobacco-related DALYs increased 116% between 1990 and 2023, reaching 6.48 million. Of this:
The researchers noted that chewing tobacco has received less attention than smoked tobacco in global tobacco-control efforts.
They said stronger prevention and cessation measures, tailored to age, sex, country and local patterns of use, are needed to reduce the burden.
Credit: iStock
Two Indian nationals have been held in the US over an alleged international scheme of smuggling and selling counterfeit Ozempic.
The US Food and Drug Administration (FDA) said Swapnadip Roy, 33, and Vicky Ramancha, 37, allegedly obtained counterfeit Ozempic from unauthorised sources in China and sold it to US distributors at deeply discounted prices between July 2023 and April 2024. Roy was extradited from Italy and has pleaded not guilty, while Ramancha remains at large.
This has raised fresh concerns about the risks of counterfeit GLP-1 medicines. The counterfeit products allegedly included fake packaging, package inserts, pen labels and needles, designed to make them appear like genuine Ozempic.
The alleged scheme continued even after the FDA seized some counterfeit products and issued a public warning in December 2023.
Counterfeit medicines may not contain the primary drug they claim to contain. The FDA warns that fake drugs can contain the wrong ingredients, too much or too little of the active ingredient, no active ingredient at all, or harmful substances.
With injectable medicines like Ozempic, contaminated or counterfeit needles can also create an infection risk.
This is particularly concerning with GLP-1 drugs because medicines like semaglutide and tirzepatide are increasingly being used for diabetes and weight management. A person buying a fake injection may therefore have no reliable way of knowing what they are actually putting into their body.
Acting FDA Commissioner Kyle Diamantas said, "Infiltrating the American drug supply with counterfeit products isn’t just a crime — it’s also a direct threat to public health and patient safety."
He added, "The FDA will continue to trace illicit networks wherever they lead, across borders and through complex supply chains, to ensure that anyone who seeks to profit off counterfeit medicines face accountability — all in our mission to keep Americans safe."
The Justice Department has stressed that the charges are allegations and that the defendants are presumed innocent unless proven guilty.
Assistant Attorney General A. Tysen Duva of the US Justice Department said, “These defendants allegedly exploited people’s health to pay themselves. We will keep pursuing anyone who seeks to deceive American consumers with counterfeit drugs.”
Also read: From 365 Shots To 52: How Could Lilly’s Newly-Approved Weekly Insulin Injection Change Diabetes Care
The FDA advises consumers to look for several warning signs.
Does the packaging look different from what you normally receive? Changes in fonts, spelling, labels, colours, printing quality or packaging can be warning signs of a counterfeit medicine.
The FDA specifically warns consumers to be cautious when buying GLP-1 medicines online. Unapproved or illegally marketed versions of semaglutide and tirzepatide may be counterfeit or contain harmful ingredients.
The agency recommends purchasing medicines only from state-licensed pharmacies.
A dramatically lower price can be a red flag, particularly when an expensive prescription medicine is being offered through an unauthorised seller. In the alleged US scheme, counterfeit Ozempic was sold to distributors at deeply discounted prices.
A new or unusual reaction after taking a medicine can also be a warning sign. The FDA lists unexpected side effects among possible indicators of counterfeit medicines.
Contact your doctor or pharmacist and verify the product before taking a dose if you suspect your medicine is fake. Patients should also avoid buying GLP-1 medicines through social-media sellers, unverified websites or other unauthorised sources.
© $2026 Times Horizon Private Limited